Difficult Intraoperative Heparinization Following Andexanet Alfa Administration.
Clin Pract Cases Emerg Med
; 3(4): 390-394, 2019 Nov.
Article
en En
| MEDLINE
| ID: mdl-31763596
ABSTRACT
Direct oral anticoagulants are now commonplace, and reversal agents are recently becoming available. Andexanet alfa (AnXa), approved by the United States Food and Drug Administration in 2018, is a novel decoy molecule that reverses factor Xa inhibitors in patients with major hemorrhage. We present a case of a 70-year-old man taking rivaroxaban with hemodynamic instability from a ruptured abdominal aortic aneurysm. He received AnXa prior to endovascular surgery, and intraoperatively he could not be heparinized for graft placement. Consideration should be given to the risks and benefits of AnXa administration in patients who require anticoagulation after hemorrhage has been controlled.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Clin Pract Cases Emerg Med
Año:
2019
Tipo del documento:
Article